An2 Therapeutics, Inc
CAGE Code: 822Z2
NCAGE Code: 822Z2
Status: Active
Type: Commercial Supplier
Summary
An2 Therapeutics, Inc is an Active Commercial Supplier with the Cage Code 822Z2.
Address
1800 El Camino Real Ste D
Menlo Park CA 94027-4103
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Jetfax Inc Sequoia Wire Co Scitor Corp Inc Anzena Systems Llc Interlynk Inc Cyladian Technology Consulting Dax And Coe Inc Fwb Software Llc Sri International Battery Express Inc Power Express Hawkins Willis Pacrim Manufacturing, Inc Electro-Nuclear Laboratories Inc Spider Technologies Inc Gupta Corp Sri Consulting Inc Ronin Decision Support Systems United States Rope Co Menlo Park Engineering Co Mitem Corp
Frequently Asked Questions (FAQ) for CAGE 822Z2
- What is CAGE Code 822Z2?
- 822Z2 is the unique identifier used by NATO Organizations to reference the physical entity known as An2 Therapeutics, Inc located at 1800 El Camino Real Ste D, Menlo Park CA 94027-4103, United States.
- Who is CAGE Code 822Z2?
- 822Z2 refers to An2 Therapeutics, Inc located at 1800 El Camino Real Ste D, Menlo Park CA 94027-4103, United States.
- Where is CAGE Code 822Z2 Located?
- CAGE Code 822Z2 is located in Menlo Park, CA, USA.
Contracting History for CAGE 822Z2 Most Recent 25 Records
- 75N93022C00059
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- 20 Sep 2022
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,306,405.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00059
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- 12 Apr 2023
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,306,405.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00059
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- 11 Jul 2023
- Development Of Epetraborole As A Novel Therapeutic For Melioidosis And Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,957,446.00
- Department Of Health And Human Services (Hhs)